Indication
Central Retinal Vein Occlusion
6 clinical trials
7 products
Product
FaricimabProduct
AfliberceptClinical trial
A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Macular Edema Secondary to Central Retinal or Hemiretinal Vein OcclusionStatus: Completed, Estimated PCD: 2022-08-09
Clinical trial
Phase I/II Randomized, Prospective, Double-masked, Sham-controlled Study of Intravitreal Autologous Bone Marrow CD34+ Stem Cell Therapy for Central Retinal Vein OcclusionStatus: Active (not recruiting), Estimated PCD: 2023-12-01
Product
BrolucizumabClinical trial
An Eighteen-Month, Two-Arm, Randomized, Double Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Adult Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein OcclusionStatus: Terminated, Estimated PCD: 2021-07-26
Product
Sham TherapyClinical trial
Phase Ib Study on Surgical Stabilizer Assisted Retinal Vein Cannulation (RVC) With tPA Infusion Confirmed by Intraoperative Angio-optical Coherence Tomography (Angio-OCT) for the Treatment of Central Retinal Vein Occlusion (CRVO).Status: Withdrawn, Estimated PCD: 2021-12-10
Product
Intravenous InfusionClinical trial
Spontaneous Retinal Artery Pulses (SPARs) as a Prognostic Determinant of Central Retinal Vein Occlusions (CRVO) in Patients With or Without Intravitreal Aflibercept InjectionsStatus: Active (not recruiting), Estimated PCD: 2025-03-23
Clinical trial
Combined Treatment of Intravitreous Bevacizumab and Triamcinolone for the Treatment or Macular Edema Secondary to Central Retinal Vein OcclusionStatus: Terminated, Estimated PCD: 2007-06-01
Product
Bevacizumab + Triamcinolone